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In  an  article  recently  published  on  the  results  of  prophylactic 
vaccination against pneumococcus pneumonia in monkeys, Cecil and 
Blake t found that subcutaneous inoculation with Pneumococcus Type 
I vaccine in doses comparable to those employed  in man did not protect 
monkeys against subsequent attacks of Pneumococcus Type I  pneu- 
monia, either spontaneous or experimental.  Vaccination did, how- 
ever, modify the course of the disease.  Invasion of the blood stream 
by  the  pneumococcus was  usually  slight  or  absent  in  vaccinated 
animals, and the proportion of recoveries was considerably higher for 
vaccinated than for unvaccinated monkeys.  In the experiments of 
Cecil and Blake, comparatively small doses of vaccine were used.  In 
view of the failure, however, of small doses of vaccine to give com- 
plete protection against pneumonia, it seemed desirable to determine 
the effect of large doses of pneumococcus vaccine. 
In the following experiments, three species of monkeys have been 
employed. Macacus  rhesus  was  used  in  three  of  the experiments, 
Macaeus syrichtus in one, and the Cebus capucinus  in one.  Macacus 
rhesus is less susceptible to pnettmococcus infection than the other 
two species, and rarely if ever develops a true lobar pneumonia.  The 
infection is more apt to be of the interstitial or confluent lobular type. 
The Philippine macaque (Macacus syrichtus) is the preferable animal 
for studying experimental pneumococcus pneumonia, as it develops a 
* Part of the funds for carrying on this work were provided by the Influenza 
Commission of the Metropolitan Life Insurance Company, New York. 
x Cecil, R. L., and Blake, F. G., J. Exp. Meal., 1920, xxxi, 519. 
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true lobar consolidation.  At the time these experiments were carried 
out, however, it was not possible to obtain this species in any con- 
siderable number.  Cebus capucinus occupies an intermediate position 
in  respect to  susceptibility  to  pneumococcus pneumonia.  In some 
cases it may present a typical lobar consolidation, but, more often, this 
species, like the rhesus,  develops only an interstitial or patchy con- 
solidation,  wMch is  usually associated with  a  heavy pneumococcus 
septicemia. 
Methods. 
The vaccine employed for these experiments was prepared from a 
stock laboratory strain of Pneumococcus Type I.  This organism was 
highly virulent, killing a mouse in quantities as small as 0.0000001  cc. 
of a 24 hour broth culture.  The vaccine was prepared as follows:  18 
to 24 hour glucose broth cultures were centrifuged, the sediment was 
washed with normal salt  solution,  and then resuspended in normal 
salt solution in such a  concentration that 0.5 cc. equalled 20 billion 
pneumococci.  The suspension was heated to  55 °  C.  for  1 hour to 
kill the pneumococci, and 0.25  per cent tricresol added as a preserva- 
tive.  With one exception (Experiment 3), the same dosage of vaccine 
was employed in all the experiments.  Three subcutaneous injections 
were given at intervals of 1 week, the first dose consisting of 20 billion 
pneumococci, the  second of 40  billion,  and  the  third  of 60  billion. 
The injections were made in  the abdominal wall,  and  caused very 
little local or general reaction. 
The culture used for testing the immunity of the vaccinated monkeys 
was the same strain of Pneumococcus Type I from which the vaccine 
had been prepared.  The method of producing experimental pneu- 
monia in monkeys has been previously described by Blake and Cecil.  ~ 
A  small  quantity  of an  18-hour broth  culture  of pneumococcus is 
introduced with a Luer syringe through the skin into the trachea.  In 
testing for resistance to pneumonia following the injection of pneu- 
mococcus vaccine, the intratracheal inoculations were made in most 
cases 2 to 3 weeks after the completion of vaccination.  The dose of 
culture injected varied from 0.01  to 0.000001  cc. for each monkey.  A 
further test of the immunity of each vaccinated monkey was made 
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by withdrawing some blood just before intratracheal inoculation, and 
carrying out protection tests in mice with the serum of the monkey. 
In most cases the monkeys died or were killed at the conclusion of 
the experiment.  Complete autopsies were performed in each instance 
and microscopic sections studied from the various lobes of the lungs. 
Active Immunity in Macacus rhesus Following  Vaccination  with Large 
Doses of Pneumococcus  Type I  Vaccine. 
The  first  experiment with  large  doses  of Pneumococcus Type I 
vaccine was carried out on rhesus monkeys. 
Experiment/.--Oct.  21, 1919.  Three Macacus rhesus monkeys (Nos. 1 to 3) 
received each 20 billion (0.S cc.) Pneumococcus  Type I saline vaccine subcutane- 
ously.  Oct.  22.  Mild  local reactions.  Oct.  28.  Each monkey received 40 
billion (1 cc.) Pncumoeoccus Type I  vaccine subcutaneously.  Nov. 4.  Each 
monkey received 60 billion (1.5 cc.) Pneumococcus  Type  I vaccine subcutaneously. 
Nov.  18.  2 weeks after last  injection of vaccine, each of the three monkeys 
received 0.000001 cc. of an 18hour broth culture of Pneumococ~xts  Type I  intra- 
tracheaUy.  An unvaccinated control monkey (No. 12) received the same amount 
of culture intratracheally. 
The results are shown in Text-fig. 1.  The three vaccinated monkeys 
remained perfectly well, showed practically no change in temperature 
or leucocyte count, and had negative blood cultures throughout the 
period of observation.  The control was sick for 3 days, developed a 
leucocytosis of 47,000,  and had a transient pneumococcus septicemia. 
All four animals were killed  on  the Sth  day following inoculation. 
The lungs in the vaccinated monkeys were entirely free from pneu- 
monia.  In the control a  small patch of interstitial pneumonia  was 
found in  the left lower lobe.  Cultures from the lungs  and heart's 
blood were sterile in all the monkeys. 
Protection  Tests.--The serums from the three vaccinated monkeys 
were tested for specific protective bodies against Pneumococcus Type 
I.  On November 18, just before intratracheal inoculation, the three 
vaccinated monkeys were  bled  for  protection  tests  in  mice.  The 
serum  of  Monkey  1  developed  a  moderate  amount  of  protective 
substance, protecting a mouse against 0.0000001  co. of Pneumococcus 
Type I  culture.  The  serum  of Monkey 2  protected mice against 
0.0001  cc. of Pneumococcus Type I  culture.  The serum of Monkey 
3  showed practically no protective power. 248  STUDIES  ON PNEUMOCOCCUS  IMAg[/NITY.  I 
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It is  evident from this experiment that  three large subcutaneous 
doses of Pneumococcus Type I  vaccine conferred complete protection 
against pneumonia.  The result, however, was unsatisfactory in one 
respect; the control developed only a small patch of interstitial pneu- 
monia  and  was  not  seriously  ill.  The  experiment  was  therefore 
repeated on the same species with larger infecting doses  of Pneu- 
mococcus Type I  culture. 
Experiment 2.--Nov. 24, 1919.  Three Macacus rhesus monkeys (Nos. 13 to 
15) received each 20 billion (0.5 cc.) Pneumococcus  Type I saline vaccine subcu- 
taneously.  Nov. 27.  Small  nodules at site of vaccine injection.  Dec. 1.  Each 
monkey received 40 billion (1 cc.) Pneumococcus  Type I vaccine subcutaneously. 
Dec.  6.  Small nodules at  site  of previous inoculation.  In  Monkey  13  the 
nodule has broken down and is discharging steril  e pus.  Dec. 7.  Each monkey 
received 60 billion (1.5 cc.) Pneumococcus  Type I vaccine subcutaneously.  Dec. 
17.  Each monkey received 0.01 cc. of an 18 hour broth culture of Pneumococcus 
Type I intratracheaUy, and an unvaccinated control monkey (No. 21) received 
the same amount (0.01 cc.) of culture intratrachealiy. 
The results are shown in Text-fig. 2.  The three vaccinated monkeys 
remained lively and well, and showed no noteworthy changes in tem- 
perature or leucocyte count.  The blood remained sterile in the three 
vaccinated monkeys.  The control monkey developed the signs and 
symptoms of pneumonia and recovered by crisis on the 6th day.  One 
of the vaccinated monkeys (No.  15)  and  the control monkey were 
killed.  The vaccinated monkey showed normal lungs.  The control 
showed a  resolving  pneumonia of the interstitial type involving the 
right upper, middle, and lower lobes and the left upper lobe.  Cultures 
taken at autopsy from the lungs and heart's blood of both monkeys 
were  sterile. 
Protection  Tests.--Blood  was  taken  from  the  veins  of  the  three 
vaccinated monkeys just  previous  to  the intratracheal inoculations 
for the purpose of determining the protective power of their serums. 
In spite of the high degree of active immunity conferred  by the vaccine, 
none of the serums showed any protection for mice. 
This  experiment corroborated  the  findings in  Experiment  1  and 
indicates that three large subcutaneous injections of  Pneumococcus 
Type I  vaccine confer complete protection against  the homologous 
type of pneumonia. Pne~mococcl  per  I cc.O~'  bhfod,  o.--.~ 
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It should be noted that in these experiments, as in the previously 
reported experiments of Cecil and Blake,  the amount of protective 
substance in  the serum of vaccinated monkeys varies widely with 
different individuals and apparently bears no close relation to local 
immunity in  the lungs,  a  phenomenon which  appears  to  be  fairly 
constant following vaccination. 
Active Immunity Following Intravenous  Vaccination with Small Doses 
of Pneumococcus  Type I  Vaccine. 
In order to determine the effect of intravenous injections of pneu- 
mococcus vaccine, three rhesus monkeys were injected intravenously 
with small doses of Pneumococcus Type I vaccine and their immunity 
was tested by intratracheal inoculation of virulent pneumococci as 
in the preceding experiments. 
Experiment 3.--Oct.  27,  1919.  Three Macacus rhesus monkeys (Nos. 4,  5, 
and 10) received each 300 million Pneumococcus  Type I  saline vaccine intrave- 
nously.  Nov.  3.  Each  monkey  received 400 million Pneumococcus Type I 
vaccine intravenously.  Nov.  4.  Monkeys lively and well.  Nov.  10.  Each 
monkey received 800 million Pneumococcus  Type I vaccine intravenously.  Nov 
11.  Animals  lively and well.  Nov. 17.  Each monkey received 1,600 million 
Pneumococcus Type I vaccine intravenously.  Dec. 2.  Each monkey received 
0.01 cc. of an 18 hour broth culture of a Pneumococcus Type I intratracheally. 
An unvaccinated control monkey (No. 17) received the same amount (0.01 cc.) 
of culture intratracheally. 
The results are shown in Text-fig. 3.  The three vaccinated mon- 
keys remained lively and well.  Monkey 10  had a  sharp  leucocyte 
reaction but showed no other signs of infection.  The control monkey 
became ill and showed symptoms of pneumonia.  One of the vacci- 
nated monkeys (No. 10) and the control monkey (No. 17) were killed. 
"~Vionkey 10  showed  an  acute  bronchitis  but  no  pneumonia.  The 
control monkey presented a complete consolidation of the right upper 
lobe,  and, microscopically,  resolving  pneumonia  of  the  interstitial 
type was demonstrated.  Cultures taken at autopsy from the lungs 
and heart's blood of these two monkeys were in both cases sterile. 
Protection Tests.--The vaccinated monkeys were bled previous to 
the intratracheal inoculations in order to  test the protective power 
of  their  serums.  Monkey  10  showed  a  high  degree of  protective =.~ 
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substance in  its  serum which protected mice against  0.0001  cc.  of 
Pneumococcus Type I culture; in Monkey 4 there was a small amount 
of protective substance, the mouse receiving 0.0000001  cc. of Pneu- 
mococcus Type I  surviving.  The  serum of Monkey 5  showed no 
protective power at all. 
This experiment demonstrates that small doses of Pneumococcus 
Type I vaccine injected intravenously confer an immunity equivalent 
to that obtained by large doses of pneumococcus vaccine administered 
subcutaneously.  This is in harmony with the observations of many 
immunologists that immunity can be obtained more readily by intra- 
venous than by subcutaneous inoculations. 
Active Immunity in Philippine Monkeys Following Vaccination with 
Large Doses of Pneumococcus Type I Vaccine. 
In view of the fact that most of the experiments carried out by 
Cecil and Blake in  their study of prophylactic vaccination against 
pneumonia  in  monkeys were  performed  on  Macacus syrichtus, it 
seemed desirable to control the result obtained in the above described 
experiments by an experiment on Philippine monkeys. 
Experiment 4.--Feb. 27,  1920.  Two Philippine monkeys (Nos. 34 and 35) 
received each 20 billion (0.5 co.) Pneumococcus Type I  saline vaccine subcu- 
taneously.  Feb. 28.  Monkeys lively and well.  Mar. 5.  Each monkey received 
40 billion (1 co.) Pneumocoecus  Type I vaccine subcutaneously.  Mar. 12.  Each 
monkey received 60 billion (1.5 co.) Pneumococcus  Type I vaccine subcutaneously. 
Mar. 30.  Each monkey received 0.000001 ce. of an 18 hour broth culture of 
Pneumococcus Type I intratracheally.  An unvaccinated control monkey (No. 
36) received the same amount (0.000001 co.) of culture intratracheaUy. 
The results are shown in Text-fig. 4.  The two vaccinated monkeys 
remained lively and well.  Their blood remained free from bacteria 
and the temperature and leucocytes showed no significant variation. 
The  control  monkey  developed  pneumonia  and  an  overwhelming 
pneumococcus septicemia and  died  on  the 5th  day of the disease. 
The two vaccinated monkeys were killed on  the 5th  day following 
inoculation.  Monkey 34 showed several clusters of small gray tuber- 
cles  but  there  was  no  pneumonie  consolidation.  The  presence  of 
tuberculosis in this monkey explains the morning and evening varia- 254  STUDIES  ON  PNEITMOCOCCUS IMMUNITY.  I 
tions in temperature (Text-fig. 4).  Monkey 35  also showed a  patch 
of encapsulated tuberculosis in the left upper lobe but there was no 
fresh consolidation.  The control monkey showed an early pneumo- 
coccus pneumonia (stage  of engorgement), involving the right  and 
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Active immunity against Pneumococcus Type  I  pneu- 
monia in Philippine monkeys following vaccination with  Pneumococcus Type I 
vaccine.  (a) and (b) Monkeys 34 and 35; each received 120 billion Pneumococcus 
Type I  vaccine subcutaneously.  (c) Monkey 36; control. 
left  lower  lobes.  Cultures  at  autopsy  from  the  lungs  and  heart's 
blood of the vaccinated monkey were sterile.  Films from the tuber- 
culous  loci  showed  tubercle  bacilli.  Cultures  from  the  lungs  and 
heart's blood of the control monkey gave Pneumococcus Type I. 
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Protection Tests.--The serums of the two vaccinated monkeys were 
tested  for  protective  substances.  Monkey  34  showed  a  definite 
amount  of  protective  substance  in  its  serum,  the  mice  receiving 
0.0000001  and 0.00001  cc.  of Pneumococcus Type I  both surviving. 
With the serum from Monkey 35 only one mouse survived--the one 
receiving 0.0000001  cc.  of culture. 
This  experiment  shows  that  even in  the  case  of  the  Philippine 
macaque, a monkey  peculiarly  susceptible  to  pneumonia,  an  ade- 
quate immunity  against  Pneumococcus Type I  pneumonia  may b,.' 
obtained by the administration of three large subcutaneous injections 
of Pneumococcus Type I vaccine. 
Active  Immunity  in  Cebus capucinus Following  Vaccination wltk 
Three Large Doses of Pneumococcus Type I  Vaccine. 
A  final test of Pneumococcus  Type I  vaccine was  carried  out  on 
the small South American ringtail.  This species was being used for 
other pneumococcus experiments and it seemed desirable to determine 
whether an efficient immunity against pneumococcus pneumonia could 
be obtained in this species by means of three subcutaneous inoculations 
of pneumococcus vaccine. 
Experiment 5.--Oct. 29, 1920.  Two Cebus capucinus monkeys (Nos. 82 and 83) 
received each 20 billion (0.5 cc.) Pneumococeus Type I  saline vaccine subcu- 
taneously.  Nov. 3.  Small nodules at  site  of previous  inoculation.  Nov. 4. 
Each monkey received 40 billion (1 cc.) Pneumococcus Type I  vaccine subcu- 
taneously.  Nov. 11.  Each monkey  received 60 billion (1.5 cc.) Pneumococcus 
Type I saline vaccine subcutaneously.  Nov. 26.  Each monkey received 0.0001 
cc. of a 24 hour  broth  culture of Pneumococcus  Type I  intratracheally.  An 
unvaccinated control monkey (No. 86) received the same amount  (0.0001 cc.) of 
culture intratracheally. 
The results are shown in Text-fig. 5.  ~fonkey 82 remained lively 
and  well  and  showed no  signs  of infection.  Monkey 83  remained 
well until  the 4th  day following inoculation,  when he unfortunately 
contracted  distemper.  An epidemic of this  disease had broken out 
among the stock monkeys and, in spite of the fact that  the subjects 
under  experiment  were isolated in  separate  cages,  Monkey 83  con- 
tracted the disease and was quite ill when he was killed on the  5th 
day following inoculation.  Autopsy showed lobar pneumonia of the 256  STUDIES  ON  PNEUMOCOCCUS  IMMUNITY.  I 
right  middle  and  left  lower lobes,  and  Bacillus bronchisepticus  was 
obtained in pure culture from the lungs.  There was no evidence of 
a  pneumococcus infection at any time during the experiment.  Mon- 
key 82 was also killed on the 5th day following inoculation and the 
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TExT-FzG. 5, a  to c.  Active immunity against Pneumococcus Type I  pneu- 
monia in Capuchin monkeys foUowing vaccinatioa with Pneumococcus Type I 
vaccine.  (a) and (b) Monkeys 82 and 83; each received 120 billion Pneumococcus 
Type I vaccine subcutaneously.  (c) Monkey 86; control. 
lungs were found free from consolidation.  Monkey 86, the control, 
died with an overwhelming pneumococcus septicemia on  the  3d day 
following inoculation.  At  autopsy  the  lungs  showed  engorgement 
and patches of incipient pneumonia in the right middle and left lower RUSSELL  L.  CECIL  AND  GUSTAV  I.  STE~I~EN  257 
lobes, and cultures taken from the lungs and from the heart's blood 
showed a pure growth of Pneumococcus Type I. 
Protection Tests.--Blood was taken from the two vaccinated mon- 
keys just  before  the intratracheal inoculations  and was  tested  on 
mice for the presence of specific protective substance against Pneumo- 
coccus Type I.  Contrary to the usual experience, no protective bodies 
could be demonstrated in either of the vaccinated monkeys. 
This experiment corroborates the results obtained in the previous 
experiments and shows that in Capuchin monkeys three large sub- 
cutaneous injections of pneumococcus Type I  vaccine confer a  high 
degree of active immunity against the homologous type of pneumonia. 
DISCUSSION. 
The experiments reported in this paper establish a  fact which has 
at least a  theoretical importance.  They demonstrate that monkeys 
can  be  completely protected  against  Pneumococcus Type  I  pneu- 
monia by means of three subcutaneous injections of Pneumococcus 
Type I  vaccine, provided sufficiently large doses are administered. 
The total dosage of vaccine employed in these studies averages about 
ten times as large as that used by Cecil and Blake in their unsuccessful 
attempts  to  vaccinate  monkeys  against  pneumonia.  It  may  be 
argued that the dosage employed in the present study could not be 
made use of in man without exciting severe local and general reactions. 
It is doubtful, however, whether such large doses would be necessary 
in the case of man.  The average, healthy human being probably 
possesses more resistance to pneumonia than the average monkey by 
reason of long continued exposure to pneumococcus infection.  Fur- 
thermore,  when monkeys are  infected artificially by  intratracheal 
inoculation, a large number of pneumococci (400 to 1,000,000) attack 
the organism at once, whereas, in spontaneous infection in man, the 
number  of  pneumococci  attacking  at  the  onset  of  pneumonia  is 
probably very small.  It would be desirable, however, to administer 
large doses of pneumococcus vaccine to man if the toxic element in 
the vaccine could be removed without injury to the antigenic element. 
The results of the protection tests carried out with the serum of 
the vaccinated monkeys are in harmony with the results reported in 
the studies of Cecil and Blake.  Protective substances may or may 258  STUDIES  ON  PNEUMOCOCCUS  IMMUNITY.  I 
not be present in  the serum of vaccinated monkeys and appear  to 
play little or no part in active immunity to pneumococcus infection 
in the lung itself. 
The intravenous administration Of pneumococcus vaccine induces 
a  higher immunity than subcutaneous injection.  The  intravenous 
method however would be much more time-consuming and this would 
be an important consideration where large groups of individuals were 
to be vaccinated. 
CONCLUSIONS. 
1.  The subcutaneous inoculation of monkeys with three large doses 
of Pneumococcus  Type I vaccine confers on them a complete immunity 
~gainst experimental Pneumococcus Type I pneumonia. 
2.  The  intravenous inoculation of  small  doses  of  Pneumococcus 
Type I vaccine also confers complete  immunity  against the homologous 
type of pneumonia. 
3.  Specific protective bodies may or may not be present in  the 
serum of monkeys vaccinated against Pneumococcus Type I.  There 
appears to be no intimate relation between active immunity against 
pneumonia and the presence or absence of protective substances in 
the serum of the vaccinated animal. 